Cite
Breast conserving therapy after neoadjuvant systemic therapy in patients with T3 breast cancer is feasible
MLA
M.E.M. van der Noordaa, et al. “Breast Conserving Therapy after Neoadjuvant Systemic Therapy in Patients with T3 Breast Cancer Is Feasible.” European Journal of Cancer, vol. 92, Apr. 2018, pp. S82–83. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........4c935c42361ee34c49d849069edb19d4&authtype=sso&custid=ns315887.
APA
M.E.M. van der Noordaa, R. Voorthuis, M.J. Vrancken Peeters, C. Loo, J. Van Urk, E.J.T. Rutgers, I. Ioan, Vincent O. Dezentjé, E. van Werkhoven, F. van Duijnhoven, Emma J. Groen, & T. Wiersma. (2018). Breast conserving therapy after neoadjuvant systemic therapy in patients with T3 breast cancer is feasible. European Journal of Cancer, 92, S82–S83.
Chicago
M.E.M. van der Noordaa, R. Voorthuis, M.J. Vrancken Peeters, C. Loo, J. Van Urk, E.J.T. Rutgers, I. Ioan, et al. 2018. “Breast Conserving Therapy after Neoadjuvant Systemic Therapy in Patients with T3 Breast Cancer Is Feasible.” European Journal of Cancer 92 (April): S82–83. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........4c935c42361ee34c49d849069edb19d4&authtype=sso&custid=ns315887.